Screening for Hepatitis B, Hepatitis C and AIDS Viruses Using Dried Blood Spot
NCT ID: NCT05390424
Last Updated: 2022-05-25
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
NA
500 participants
INTERVENTIONAL
2022-06-30
2023-09-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
A Study to Evaluate the Effects of Anti-HIV Drugs in HIV-Positive Patients Who Also Have Hepatitis C Infection
NCT00001117
HIV-1 Resistance at Screening for HIV Prevention Studies
NCT01204814
Combined Injectable Treatment for HIV and OUD
NCT05991622
A Study to Monitor the Health of Participants in HIVNET 014 Who Become Infected With HIV-1
NCT00001121
Feasibility of Interventions on People Who Inject Drugs in Vietnam
NCT02573948
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
DIAGNOSTIC
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Drug user
Drug users will be screened for Hepatitis C, Hepatitis B and AIDS using Dried Blood Spot for blood collection
Blood collection using Dried Blood Spot
Drug users will be screened for Hepatitis C, Hepatitis B and AIDS using Dried Blood Spot for blood collection
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Blood collection using Dried Blood Spot
Drug users will be screened for Hepatitis C, Hepatitis B and AIDS using Dried Blood Spot for blood collection
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Person on opiate substitution therapy
Exclusion Criteria
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
University Hospital, Rouen
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Ghassan RIACHI, MD
Role: PRINCIPAL_INVESTIGATOR
University Hospital, Rouen
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
CSAPA la Boussole
Rouen, , France
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2021/098/HP
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.